Why the study?
Can plasma methotrexate data identify patients at risk for serious toxicity during high dose therapy for solid tumors?
Population
Patients with solid tumors undergoing high dose methotrexate therapy (111 infusions studied)
Design
Cohort
Authors
Loading...
Plasma MTX monitoring may flag toxicity risk in high-dose therapy; leaves open prospective validation before routine use.
Can plasma methotrexate data identify patients at risk for serious toxicity during high dose therapy for solid tumors?
Pharmacokinetic monitoring of high-dose methotrexate can identify patients at risk for serious toxicity.
Isacoff et al. (1976) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: